Cipla vs Apollohosp Q3 FY25

Cipla reported Q3 FY25 revenue of INR 7,073 crore (+8% YoY) and EBITDA margin of 28% (+184bps YoY), driven by strong India (10% growth), South Africa (21% ZAR), and EMEU (20% USD) performance. US revenue was $226M, impacted by lanreotide supply disruption, but Albuterol market share reached 21%. Management reiterated FY26 top-line growth guidance and expects EBITDA for FY25 to exceed the 24.5%-25.5% range. Key catalysts include generic Advair launch in H1 FY26 and Abraxane in H2 FY26 from the now-cleared Goa facility. Risks include regulatory delays at Bengaluru and MDI facilities, and potential US tariff impacts, though US manufacturing de-risks some exposure.

Guidance read

FY26 top-line growth guidance retained: Management reiterated guidance to grow top line in FY26, with further profitability guidance to be provided after budget finalization. Generic Advair launch in late H1 FY26: Cipla plans to launch generic Advair from its US facility in late first half of FY26, with de-risking progressing as expected. Abraxane launch in H2 FY26: Abraxane launch expected from Goa facility post-approval, likely in back end of second half FY26 (Q4 FY26). FY25 EBITDA margin to exceed guidance: EBITDA for FY25 is trending higher than earlier guidance of 24.5%-25.5%, with Q3 margin at 28% but not sustainable.

Risk read

Key risks include Regulatory delays at Bengaluru and MDI facilities — US FDA issued Form 483 observations at Virgonagar (Bengaluru) and MDI facilities; official classification awaited, potentially delaying product approvals.; Lanreotide supply disruption recovery timeline — Lanreotide supply issues impacted US revenue; management expects normalization by end of Q4, but full capacity recovery may extend into Q1 FY26.; US tariff policy uncertainty — Potential US tariffs on pharmaceutical imports could impact margins; management noted de-risking via US facilities but awaits policy clarity.; Generic Revlimid revenue decline — Revlimid revenue is flat sequentially and expected to decline as competition increases; new launches may only partially offset the reduction..

Promise ledger

Of 1 tracked promise, management 0 met, 0 close, 1 missed.

Apollo Hospitals delivered a strong Q3 FY25 with consolidated revenue of INR 5,527 crore (+14% YoY) and EBITDA of INR 762 crore (+24% YoY). PAT surged 52% YoY to INR 372 crore, driven by mid-teens growth across all segments and margin expansion in healthcare services (24.1% EBITDA margin). The hospital business saw 13% revenue growth, with high-margin CONGO specialties (cardiac, oncology, neuro, gastro, ortho) growing at 10.35% volume, offsetting a 1.5% revenue drag from Bangladesh patient decline. Apollo HealthCo (pharmacy & digital) grew 15% YoY, with digital losses narrowing. Management guided for calibrated bed additions (1,737 beds over FY26-27) with minimal margin impact (~100 bps), and expects Apollo 24/7 to break even by Q2/Q3 FY26. Key risk: slower-than-expected recovery in Bangladesh patient inflows and competitive pressure in digital pharmacy.

Guidance read

Apollo 24/7 break-even by Q2/Q3 FY26: Digital platform expected to achieve EBITDA break-even by end of Q2 or Q3 of next fiscal year, with GMV target of INR 900-1,000 crore. Hospital margin trajectory ~24% despite new beds: Healthcare services EBITDA margin expected to remain around 24% next year, with new bed openings impacting margins by no more than 100 bps. New hospital commissioning schedule: Pune and Kolkata hospitals to open in H1 FY26; Hyderabad and Gurugram by end of FY26; 50% of 1,737 beds operational in FY26, rest in FY27. HealthCo revenue target of INR 25,000 crore by FY27: Apollo HealthCo (including Keimed) targets INR 25,000 crore revenue and 7-8% EBITDA margin by FY27.

Risk read

Key risks include Bangladesh patient decline persists — Bangladesh patient footfall dropped, causing 1.5% revenue impact; management is exploring other international markets but recovery timeline uncertain.; Digital pharmacy competitive pressure — Analyst raised concerns about high ESOP costs and competition from startups; management acknowledged but defended ESOP as retention tool.; New bed ramp-up risk — Large capacity addition (1,737 beds) could pressure margins if occupancy ramps slower than expected; management expects 100 bps margin impact..

Promise ledger

Of 1 tracked promise, management 0 met, 0 close, 1 missed.